Additional file 1: of Interventions to reduce post-acute consequences of diarrheal disease in children: a systematic review

Supplement. (DOCX 129 kb

Overlapping toxicities of anti-tuberculosis drugs and ARV.

<p>Overlapping toxicities of anti-tuberculosis drugs and ARV.</p

Association predictors and death, cure, culture conversion, and smear conversion.

1<p>Adjusted for TB resistance pattern as indicator variables.</p>2<p>Adjustment not possible because less than 6 patients with ODR and none with XDR.</p

Patient characteristics by ART use.

1<p>N's may not add up to total N because of missing values.</p>2<p><i>p</i>-values of ART use vs. non-use comparisons based on the categorical version of variable are presented unless interpretation of p-value based on of continuous version differed.</p>3<p>Effective drug: Demonstrated susceptibility to drug by sputum culture.</p

Details of included studies.

1<p>Data from routine TB surveillance system of the TB Division State of Sao Paulo identified through 2003 thereby representing a larger study population than those included in the referenced abstracts.</p>2<p>Nested in larger cohort study, which is the design from which we pulled data.</p>3<p>Cure, culture and smear conversion data not presented in publication.</p

Kaplan Meier Curve for cure comparing ART vs. no ART among all-patients (N = 216).

<p><i>Note: 1 additional cure event occurred at month 60</i>.</p

Flow diagram for study inclusion.

<p>Two authors each sent data that was represented by two included studies, therefore 12 references actually included. ¹ Lew W, Pai M, Oxlade O, Martin D and Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008;149:123–34. ² Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6:e1000150. <b>Reasons for Exclusion II.</b> Inappropriate study design (n = 34); Outcomes of interest are not measured (n = 22); Not deemed research/no data collected (n = 18); No TB drug resistance or drug resistance testing (n = 21); No HIV+ patients or HIV-testing (n = 37); No TB-infected patients or TB treatment (n = 4); No 2^nd line drug TB therapy used (n = 16); No ART data collected (n = 3); Author contacted for another study/same patients (n = 12). <b>Other Reasons for Exclusion III (other n = 11):</b> Not interested (n = 1); Inappropriate study design (n = 1); No HIV (n = 3); In process of publication (n = 1); Already contacted (n = 5).</p